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Identity 
Other names: DKFZp547O146; FBI-1; FBI1; LRF; 
MGC99631; ZBTB7; ZNF857A; pokemon 
HGNC (Hugo): ZBTB7A 
Location: 19p13.3 
Local order 
- EEF2 (19pter-q12) eukaryotic translation elongation 
factor 2 
- SNORD37 (19p13.3) small nucleolar RNA, C/D box 
37 
- PIAS4 (19p13.3) protein inhibitor of activated STAT, 
4 
- ZBTB7A (19p13.3) zinc finger and BTB domain 
containing 7A 
- MAP2K2 (19q13.3) mitogen-activated protein kinase 
kinase 2 
- CREB3L3 (19p13.3) cAMP responsive element 
binding protein 3-like 3 
DNA/RNA 
Description 
Size: 21601 bases. 
Orientation: minus strand. 
Cloning of the 5'-upstream region of ZBTB7A 
revealed: a) the absence of putative TATA and CCAAT 
sequences, b) the presence of two consensus sequencs 
for the binding transcription factor Sp1, SpA (-
641~636-) and SpB (-972~-967), as well as consensus 
sequences for the AP-1, AP-2, PU.1, Hb, CBF-1, 
GATA-1 elements and p53-binding sites, c) the  
presence of three regulatory elements, POS-D, NEG-U 
and NEG-D, with a key role in the regulation of the 
Pokemon gene. 
The nucleotide sequence from -83 to -71 contains the 
positive element POS-D, which is necessary for the 
strong activity of the Pokemon promoter. The region 
from -558 to -541 contains the NEG-U element, 
involved in the negative regulation of the Pokemon 
promoter. The region from -128 to -108, namely NEG-
D, is also necessary for the negative regulation of the 
Pokemon promoter. Neither NEG-U nor NEG-D 
element alone can negatively affect Pokemon 
expression. Pokemon promoter activity is greatly 
dependent on the interaction (cooperation) between 
NEG-U and NEG-D elements. This synergistic 
inhibition on Pokemon expression requires a specific 
length between the regulatory elements. Once this 
distance is reduced, the interaction between the NEG-U 
and NEG-D elements is almost abolished. 
Transcription 
The gene is comprised of 3 exons, building a main 
transcript of 4456 bps. 
Alternative splicing 
Pokemon transcripts can be alternatively spliced, 
resulting in four mRNAs with different 5'-untranslated 
regions. The four alternative first exons are located at -
11596, -10224, -9109 and -17 bp upstream of the 
translation start site of Pokemon, implying that 
Pokemon can putatively be regulated by four 
alternative promoters. 
Pseudogene 
There are no known pseudogenes. 
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ZBTB7A protein is composed of 584 amino acids (a.a.) 
with a molecular weight of 86 kDa. It belongs to the 
POK (POZ and Krüppel) family of transcriptional 
repressors. Members of this family have a characteristic 
structure, containing a NH2-terminal POZ/BTB domain 
(poxvirus zinc finger/broad-complex tramtrack, bric-à-
brac) and a COOH-terminal domain, consisting of 
C2H2 Krüppel-type zinc fingers, "surnamed" due to 
resemblance with the Drosophila segmentation protein 
Krüppel. Due to this structure, they are also known as 
POZ/ZF proteins. At the C-terminus a bipartite nuclear 
localization signal (NLS) is located. 
POZ/BTB domain represents a 120 a.a. evolutionary 
conserved domain, present in more than 200 human 
proteins, which mediates protein-protein interactions. It 
is responsible for homodimerization as well as 
heterodimerization mediating the recruitment of 
corepressor complexes, such as nuclear co-repressor 
(N-CoR), silencing mediator of retinoic acid (SMRT), 
B-CoR (Bcl-6 co-repressor), mSin3A (SIN3 homolog 
A, transcription regulator) to the target genes. This also 
facilitates the binding of histone deacetylases within 
the target genes leading to its transcriptional repression. 
It also interacts with Sp1 zinc finger proteins. 
C2H2 Krüppel-type zinc finger domain, found in more 
than 600 human proteins, represents a 25-30 a.a. 
domain, responsible for specific DNA recognition and 
binding. It is characterised by two conserved cysteine 
and histidine residue pairs that coordinate a single zinc 
atom. 
Expression 
ZBTB7A is expressed in all proliferating cells. 
ZBTB7A is highly expressed in malignant tissues than 
in the corresponding benign or normal tissue (breast, 
lung, prostate). 
Localisation 
ZBTB7A is constitutively nuclear, due to a Nuclear 
Localization Signal (NLS) located at the C-terminus 
(a.a. 498-502). Immunohistochemical (IHC) studies of 
ZBTB7A expression in NSCLCs (Non-small cell lung 
carcinomas) have shown a nuclear signal. In NSCLCs 
the immunostaining is prevalent in the cancerous nests, 
whereas few tumour-associated stromal cells and a 
small number of parabasal intermediate cells in the 
adjacent normal bronchial epithelium, are positively 
stained. ZBTB7A nuclear expression was also 
prevalent in malignant breast tissues and surrounding 
fibroblasts and lymphocytes, whereas stromal cells 
were weakly stained. 
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Schematic representation of human ZBTB7A protein structure. POZ domain: 24-131, ZF: 376-489, NLS: 489-503. 
 
Function 
ZBTB7A has a variety of biological functions. 
ZBTB7A was originally identified as a factor binding 
to a specific sequence within the human 
immunodeficiency virus, type 1 promoter, and can 
physically interact with other POK family members 
such as BCL-6. Co-expression of ZBTB7A and BCL-6 
in lymphoma, predicts the clinical outcome. ZBTB7A 
is also implicated in differentiation processes like 
osteoclastogenesis, chondrogenesis and adipogenesis. 
Furthermore, ZBTB7A knockdown in mice, results in 
embryonic lethality due to severe anaemia and 
impaired cellular differentiation. 
ZBTB7A is a transcription factor which regulates the 
expression of many proteins, such as extracellular 
matrix collagen types I, II, IX, X and XI, fibronectin, 
elastin, human cartilage oligomeric matrix protein, 
p19ARF tumour suppressor and the c-fos and c-myc 
oncoproteins by binding to consensus sequence within 
their promoters. ZBTB7A preferable binding sites 
include either a single guanine-rich site or two half-
sites, each with the consensus sequence 
G(A/G)GGG(T/C)(C/T)(T/C)(C/T), with a variety in 
spacing and orientation, supporting that ZBTB7A can 
bind to the DNA with great flexibility. In other cases, 
the interaction between Pokemon POZ domain and 
other transcription factors, such as Sp-1 or the p65
subunit of NF-kappaB, is necessary for its regulatory 
role. 
ZBTB7A self-associates, as depicted in vivo and in 
vitro, via both its POZ domain and its zinc finger (ZF) 
domain. ZBTB7A can act as a transcriptional repressor 
or activator depending on the promoter context. 
Finally, it plays a crucial role in cell tumorigenesis. 
- Transcription regulator 
1. ZBTB7A/FBI-1 + IST (HIV) 
FBI-1 binds to IST, the HIV-1 inducer of short 
transcripts, and mediates its function. The first and 
second zinc fingers are required for efficient binding. 
FBI-1, via the zinc finger domain, interacts as well with 
Tat (transactivator of transcription), a viral 
transactivator protein, responsible for the synthesis of 
HIV-1 full-length transcripts. FBI-1 partially 
colocalizes with Tat and enhances its activity in a dose 
dependent manner, therefore modulating Tat-activated 
HIV-1 transcription. 
2. FBI-1 + adipogenesis 
FBI-1 acts as a dual regulator in adipogenesis. It 
promotes preadipocyte differentiation process and 
facilitates adipogenesis. On the other hand, it is 
implicated in termination of the mitotic clonal 
expansion, in which growth-arrested preadipocytes re-
enter the cell cycle and complete two rounds of cell
division, followed by terminal differentiation phase. 
3. FBI-1 + FASN (transcriptional activator) 
Increased FBI-1 expression enhances FASN (fatty-acid 
synthase gene) expression, in stable cancer cells or 
immortalised stable cells. FASN expression appears to 
be low in almost all nonmalignant adult tissues, but is 
highly expressed in many carcinomas, where it is 
responsible for fatty acid synthesis. Furthermore, 
knockdown of FBI-1 expression leads to decreased 
FASN expression. 
FBI-1 enhances FASN transcriptional activation 
through SREBP-1a (sterol-responsive element (SRE)-
binding protein 1). FBI-1 and SREBP-1a form a 
complex and co-localize mainly in the nucleus. 
Specifically, FBI-1 through its ZFDBD-C-term domain 
(zinc finger DNA binding domain) interacts directly 
with the bHLH domain of SREBP-1. Sp1 binds to the 
proximal GC-box of the FASN promoter and acts as a 
major activator. It has been found that the regulatory 
elements GC-box and SRE/E-box of FASN promoter 
can be bound by all three, FBI-1, SREBP-1a and Sp1,
transcription factors. This can lead to a binding 
competition between them. 
4. FBI-1 + NF-kappaB (transcriptional activator) 
FBI-1 POZ domain interacts directly with the RHD 
domain (Rel homology domain) of NF-kappaB p65 
subunit. 
FBI-1 enhances the transcription of NF-kappaB-
responsive genes, like E-selectin, by increasing either 
the localization or stability of NF-kappaB in the 
nucleus. FBI-1 facilitates nuclear import and prolonged 
nuclear retention of the p65 subunit of NF-kappaB, 
either by inhibiting its export to the cytoplasm, or by 
increasing its stability. In addition, FBI-1 inhibits 
IkappaB (inhibitors of NF-kappaB) interaction with 
NF-kappaB, eventually enhancing NF-kappaB 
transcription in the nucleus. 
5. FBI-1 + ADH5/FDH (transcriptional repressor) 
FBI-1 POZ domain interacts with the C2H2-type zinc-
finger domain of Sp1 (Specificity protein 1), thereby 
repressing the ADH5/FDH promoter activity. 
6. ZBTB7A + ARF (transcriptional repressor) 
ZBTB7A was characterized as a potential proto-
oncogene that specifically represses transcription of 
p14ARF, a major tumour suppressor gene, (leading 
indirectly to p53 inactivation). ZBTB7A binds directly 
to p19ARF promoter (mouse homologue). ARF 
promoter contains several putative ZBTB7A-binding 
sites, rich in GC. However the one located 50 base 
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pairs upstream from the transcription start site is 
indispensable for p19ARF repression. 
7. FBI-1 + p21WAF1/CIP1 (transcriptional repressor) 
FBI-1 represses transcriptional activation of P21CIP1, 
by the following ways. 
Firstly, by inhibiting ARF and Hdm2 expression, and 
therefore p53, it indirectly affects p21WAF1/CIP1 
expression. Secondly, as a GC-box-binding 
transcription factor, it competes with Sp1 
(transcriptional activator) to bind to the GC-rich 
FRE/GC-box 3 element at the proximal promoter, 
critical for p21CIP1 transcription. 
Furthermore FBI-1 competes with p53 for binding to 
the distal p53-binding elements of p21WAF1/CIP1 and
represses its transcription. 
Additionally, it interacts with corepressors such as
NCoR (Nuclear receptor co-repressor), SMRT 
(silencing mediator for retinoid and thyroid receptors), 
and mSin3A and recruits HDAC complexes, leading to 
histone deacetylation at the proximal promoter, 
responsible for p21WAF1/CIP1 transcriptional 
repression. 
8. FBI-1 + CCS-3 + p21WAF1/CIP1 
FBI-1 suppresses p21WAF1/CIP1 promoter activation 
by more than 70% by acting on both the proximal Sp1
binding GC-box 3 element and the distal p53 
responsive regulatory elements. CCS-3, (cervical 
cancer suppressor -3), represents an isoform of eEF1A 
(eukaryotic translation elongation factor 1A), involved 
in various processes like embryogenesis, oncogenic 
transformation, senescence, cell proliferation, and 
cytoskeletal organization. CCS-3 enhances the FBI-1 
mediated p21WAF1/CIP1-transcriptional repression, 
by another 30-50%. The above is accomplished 
because CCS-3 can interact with both co-repressors, 
(like SMRT and NCoR independently of FBI-1) and 
FBI-1 POZ domain. CCS-3 is able to recruit additional 
transcriptional co-repressor-HDAC complexes when 
bound to the FBI-1 POZ-domain, therefore enhancing 
FBI-1 transcriptional repression potential. 
Furthermore, both FBI-1 and CCS-3 independently 
promote cell proliferation. Co-transfection of CCS-3 
and FBI-1 results in a significant increase in cell 
population. 
9. LRF - COMP (transcriptional repressor) 
LRF (mouse homolog of FBI-1) binds directly to the 
NRE element and specifically to a nine nucleotide 
(GAGGGTCCC) sequence - LRF binding element 
(LBE) in COMP (Cartilage oligomeric matrix protein) 
gene promoter. NRE represents a negative regulatory 
element, both necessary and sufficient to repress 
promoter activity. Therefore, it regulates COMP gene 
expression implicated in chondrogenic differentiation. 
Human COMP gene promoter also contains a typical 
consensus site (GGGGGCCTC, -1294 to -1302) for 
binding LRF/FBI-1, implying that FBI-1 may suppress 
COMP gene expression in human as LRF does in the 
mouse. 
10. FBI1 - AR (transcriptional repressor) 
The androgen receptor (AR) is important for the 
proliferation and functioning of prostate cells. 
FBI-1 physically interacts with AR and when 
overexpressed, it represses AR transcriptional activity 
in a ligand-dependent manner. More precisely, POZ 
domain of FBI1 is responsible for the interaction with 
the LBD domain (C-terminal ligand-binding domain) 
of AR. Furthermore, full-length FBI-1 is indispensable 
for the repression of AR transcriptional activity. On the 
contrary, FBI-1 suppression by siRNA enhanced AR 
transcriptional activity. 
It is known that FBI-1 can interact with NCoR and 
SMRT, which are co-repressors of AR. (FBI-1 
exhibited a much stronger interaction with SMTR 
compared to that with NCoR). It was shown that FBI-1 
enhances the recruitment of NCoR and SMRT to 
endogenous ARE elements and through this mechanism 
it suppresses AR transcriptional activity. This notion is 
further supported by the fact that FBI-1 repressive 
effect on AR transcriptional activity, is inhibited upon 
endogenous NCoR and SMRT knockdown. 
Furthermore it was suggested that FBI-1 could recruit a 
co-repressor complex harbouring HDACs, resulting in 
repression of AR functions in the presence of R1881 
(synthetic agonist of the androgen receptor). Last, it 
was shown that FBI-1 can play different roles in 
regulating androgen-dependent (LNCaP) and -
independent (PC-3) prostate cancer cells. It inhibits 
LNCaP cell proliferation in the presence of R1881, 
whereas no difference in proliferation was observed in 
the absence of R1881. In contrast, knockdown of FBI-1 
by siRNA led to a significant increase in LNCaP cell 
growth. Interestingly, either in the presence or absence 
of R1881, PC-3 cell proliferation was dramatically 
enhanced upon FBI-1 overexpression. 
11. Pokemon - survivin (transcriptional activator) 
Tissue microarray technology has shown Pokemon 
overexpression in 86,8% of breast cancer tissue, but not 
in normal breast tissue. Furthermore Pokemon 
expression correlated positively with tumor size, lymph 
node metastasis and poor patient survival. 
Survivin, a member of the inhibitor of apoptosis 
proteins (IAP), is implicated in cell carcinogenesis and 
tumor progression. 
Survivin and Pokemon expression levels were found to 
be highly correlated in human breast cancer cells. 
Pokemon induces survivin expression by direct binding 
to the GC boxes in its promoter. 
- Relation with ASF/SF2 through miRNAs 
LRF is regulated by microRNA (miRNA) families. 
In MEFs (Mouse Embryo Fibroblasts) it was shown 
that miR-28 and miR-505, which are negatively 
controlled by LRF, can affect ASF/SF2 (Alternative 
Splicing Factor/Splicing Factor 2) expression and 
therefore can induce apoptosis or cellular 
transformation. Deregulation of the LRF/miR-28/miR-
505/ASF/SF2 axis affects the MEF 
senescence/apoptosis pathway. 
- Relation with anticancer agents 
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Curcumin is a natural compound known for its 
antioxidant, anti-inflammatory and anticarcinogenic 
properties, since it can inhibit the proliferation a d 
induce the apoptosis of cancer cells, such as gastric, 
colon, breast. Curcumin inhibits ZBTB7A 
transcriptional activation, by suppressing the Sp1 
stimulatory effect on Pokemon promoter, as it inhibits 
Sp1 recruitment to the Pokemon promoter. 
- Global mapping of ZBTB7A downstream target genes 
in HepG2 cells 
ChIP-on-chip analysis performed in the human hepato-
carcinoma cancer cell line HepG2, revealed 556 genes 
as potential direct targets of ZBTB7A. These genes ar  
mainly divided in three categories: genes regulating 
metabolism, transcriptional regulators and cell signal 
transduction genes. Among the most ZBTB7A-targeted 
metabolic pathways are the aminosugar, arachidonic 
acid, tryptophan, pyrimidine and purine metabolic 
pathways. Moreover sucrose, vitamin B6, valine, 
leucine and isoleucine, folate, fatty acid and 
glycerolipid metabolism, are characterized as ZBTB7A 
regulatory targets. As far as signal transduction is 
concerned, ZBTB7A might play a regulatory role on 
the MAPK signalling pathway. Furthermore, four genes 
involved in axon guidance, a key stage in the formation 
of the neuronal network, are directly regulated by 
ZBTB7A expression in HepG2 cells. This pinpoints to 
a potential regulatory role for ZBTB7A in neural 
development. 
- ZBTB7A and SUMOylation 
ZBTB7A can be sumoylated as it contains an amino-
acid sequence highly similar to the SUMO-1 conjugate 
consensus motif, ψKXE (ψ: large hydrophobic residue, 
K: lysine to which SUMO-1 is conjugated, X: any 
amino acid, and E: glutamic acid). Sumoylation of 
several lysine residues of ZBTB7A is important in 
order to achieve full repressive activity. 
Homology 
LRF (leukemia/lymphoma-related factor) is the mouse 
homologue of FBI-1. It co-immunoprecipitates and co-
localizes with Bcl-6 and is involved in chondrogenesis 
and adipogenesis. 
OCZF (osteoclast-derived zinc finger), the rat 
homologue of FBI-1, is a transcription repressor, 
involved in osteoclastogenesis. Mouse LRF and rat 
OCZF are 90 and 96% identical at the nucleotide and 
amino acid levels, respectively. Mouse LRF and human 












Since ZBTB7A specifically represses transcription of 
p14ARF, a major tumor suppressor gene, it was 
characterized as a potential proto-oncogene, expected 
to play a significant role in carcinogenesis. ZBTB7A 
null MEFs (ZBTB7A-/-) had higher p19ARF protein 
levels than wild-type MEFs and resisted to proliferation 
and transformation upon oncogenic stimulation. The 
oncogenic nature of ZBTB7A was also examined in 
vivo in transgenic mice, which overexpressed ZBTB7A 
in T and B lymphoid lineage cells. These mice 
developed thymic lymphomas and tumour infiltration 
into bone marrow and poor survival compared to the 
wild-type ones. 
ZBTB7A is overexpressed in diffuse large B cell 
lymphomas (DLBCL) and follicular lymphomas, as 
well as in anaplastic large cell lymphoma and 
angioimmunoblastic lymphoma, as far as T-cell 
malignancies are concerned.  
ZBTB7A oncogenic role in human malignant gliomas 
was revealed with comparative genomic hybridization 
analysis (bioinformatics methods).  
Tissue microarray analysis revealed ZBTB7A 
overexpression in colon, prostate, bladder, as well as in 
breast and lung carcinomas.  
IHC and immunofluorescence analysis revealed a 
significantly higher expression of LRF protein in 
malignant breast specimens than in the corresponding 
benign or normal tissue, with a clear nuclear expression 
pattern. 40% and 15% of benign breast biopsy tissues 
expressed LRF mRNA transcripts and protein, 
respectively, probably because they contain 
premalignant cells and adipocytes.  
Ductal hyperplasia showed weak LRF staining, 
whereas in invasive ductal carcinoma and invasive 
lobular carcinoma strong nuclear expression of LRF 
was observed.  
In breast cancer tissues ZBTB7A expression levels 
were significantly correlated with histological grade, 
implying a potential role of ZBTB7A in breast cancer 
development, whereas were inversely correlated with 
the oestrogen receptor status. No correlation was 
confirmed between ZBTB7 overexpression and tumour 
size, stage, lymph node status, or PR status. However 
its overexpression predicted poorer overall survival and 
was associated with shorter recurrence-free survival.  
In addition, ZBTB7A is expressed in the nuclei of 
human colon, renal, hepatocellular carcinomas, 
mesotheliomas and thymoma tumor cells. 
IHC and immunoblotting analysis showed ZBTB7A 
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adjacent normal tissue elements. Gene amplification 
proved to be a relatively frequent event leading to 
ZBTB7A overproduction in NSCLCs. Furthermore, a 
positive correlation between ZBTB7A expression and 
proliferation, as well as tumour size, was revealed. 
Survival analysis correlated ZBTB7A overexpression 
with poor prognosis. ZBTB7A expression is not 
associated with the NSCLC patients' sex, age, lymph 
node stage, tumor differentiation degree and histology. 
Furthermore IHC, immunoblotting and PCR analysis 
revealed significantly higher ZBTB7A (FBI-1) protein 
and mRNA expression levels in ovarian cancer samples 
and cell lines, compared to benign or borderline 
tumours. Gene amplification was proved to be, to a 
great proportion, the underlying mechanism of 
ZBTB7A overexpression in ovarian cancers. 
Upregulated ZBTB7A expression was found in 
metastatic foci and malignant ascites and was 
associated with advanced stage, poor overall survival 
and disease-free survival. Additionally, it was shown 
that ZBTB7A plays an important role in ovarian cancer 
cell migration, proliferation and invasiveness, through 
its direct binding to the promoter of MT1-MMP 
(membrane type 1-matrix metalloproteinase), which 
enhances MT1-MMP promoter activity. 
Moreover, ZBTB7A (LRF) is implicated in the 
pathogenesis of prostate cancer, since IHC, Western 
blot and PCR analyses revealed a significantly higher 
expression of LRF mRNA transcripts and protein in 
prostate cancer (PC) specimens than in benign prostate 
hyperplasia (BPH). A significant increase in LRF 
mRNA transcripts and protein levels was observed 
when normal human prostate cells (RWPE-1) as well as 
prostate cancer cells, (LNCaP androgen sensitive 
prostate cancer cells and PC-3 androgen-insensitive 
prostate cancer cells), were treated with EGF 
(epidermal growth factor). 
Recently, the development of a novel strategy for 
silencing Pokemon in vivo, with promising results, 
provided a marked anti-tumour activity in nude mice. 
Cell growth and proliferation 
Note 
ZBTB7A is implicated in cell growth regulation, as it 
transcriptionaly represses Rb (Retinoblastoma), a gene 
involved in differentiation, cell cycle control, and 
tumor suppression. FBI-1, through its POZ domain, 
recruits HDACs to deacetylate histones H3 and H4 
around the Rb proximal promoter region, resulting i 
Rb transcriptional repression. Additionally, FBI-1 
binds to the 4 FREs (FBI-1 binding sites, GC-rich) on 
the Rb promoter and relatively strongly to the FRE2 
element. 
FBI-1 enhances cellular transformation as well. FBI-1 
overexpression in HeLa cells resulted in formation of 
large foci and increased the number of HeLa cells in S 
phase. Moreover ZBTB7A is involved in cell 
proliferation in MEFs. 
Differentiation 
Note 
ZBTB7A is implicated in many differentiation 
processes including osteoclastogenesis, chondrogenesis 
and adipogenesis. ZBTB7A knockdown in mice 
resulted in embryonic lethality due to severe anaemi  
and impaired cellular differentiation. LRF was found to 
be essential for terminal fetal erythropoiesis. LRF is a 
downstream target of GATA1. GATA1 is a 
transcription factor significant for erythroblasts 
differentiation, maturation and protection from 
apoptosis. GATA1 binds directly to the two putative 
GATA-binding sites in ZBTB7A promoter region and 
activates its expression. Additionally, in the absence of 
LRF, both in embryos and adults, BIM a significant 
apoptosis inducer in hematopoietic cells was markedly 
upregulated. LRF directly binds to BIM proximal 
promoter region, which contains four potential LRF 
binding sites and represses its expression, during the 
late stages of erythroid differentiation. On the other 
hand, BIM loss rescues LRF knockout mice from fetal 
anemia. 
From the above, it is resumed that the suppression of 
BIM-mediated apoptosis by LRF, which in turn is 
activated by GATA-1, is critical for effective 
erythropoiesis. 
RANK and its ligand, RANKL (a member of the tumor 
necrosis factor - TNF superfamily), are critical 
molecules in osteoclastogenesis. RANKL also plays an 
important role in inflammatory bone loss. FBI-
1/OCZF/LRF is highly expressed in osteoclasts and is 
an important regulator of RANKL-induced 
osteoclastogenesis. LRF siRNA inhibits osteoclast 
differentiation. Osteoclast formation is a crucial step in 
bone destruction in chronic arthritis. FBI-1/OCZF is 
highly expressed in osteoclasts in inflammatory 
arthritis, implying a role in inflammatory bone erosi n. 
The above suggest that by enhancing 
osteoclastogenesis and survival of osteoclasts, FBI-
1/OCZF/LRF might play important roles in bone 
destruction in vivo, including the bone loss and 
remodelling that occurs in chronic inflammatory 
arthropathies, such as rheumatoid arthritis. 
Regulation of B lymphopoiesis 
Note 
LRF (mouse homologue of ZBTB7A) regulates B 
lymphocytes development from lymphoid-restricted 
progenitors in mice, versus T lymphoid fate. 
Knockdown of LRF in HSCs (hematopoietic stem  
cells) and CLPs (common lymphoid progenitors), 
impaired B cell development and resulted in 
extrathymic T cell development in the bone marrow 
(BM). Furthermore, LRF blocks Notch signalling 
pathway in normal HSCs. This pathway is essential for 
T cell development. Notch deletion in mouse HSCs 
results in a decreased number of thymic T cells, 
whereas it enhances B cell development in the thymus.  
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Moreover, LRF regulates mature B cell lineage fate and
humoral immune responses, through the obligatory 
formation of a dimer in B cells, important for its 
function. Furthermore, LRF inactivation in transformed 
B cells attenuated their growth rate. The above suggest 
the potential targeting of LRF dimmers as a treatment 
of autoimmune diseases and B cell malignancies. 
LRF bypasses RASV12-induced 
senescence 
Note 
LRF enhances E2F-dependent transcription, with an 
unknown mechanism, which does not include Rb 
downregulation. LRF synergizes with RASV12 in 
inducing E2F. LRF bypasses RASV12-induced 
senescence by activating E2F-target genes, such as 
Cyclin E, Cyclin A and p107. Specifically, Cyclin E is 
shown to be indispensable, but not sufficient for LRF-
mediated bypass of RASV12-induced senescence. The 
above mentioned bypass occurs independently of 
critical senescence inducers, such as p19ARF, p21CIP 
and p16INK4A. 
LRF is post-transcriptionally controlled 
by MiR-20a: implications in senescence 
Note 
MicroRNAs (miRNAs) are short 20-22 nucleotide 
RNA molecules, which act as post-transcriptional 
suppressors. They repress mRNA translation by base 
pairing to 3'UTR sequences. 
Mir-20a, a member of miR-17-92 cluster, can interact 
directly with ZBTB7A 3'UTR. Upon miR-20a 
overexpression in MEFs, LRF protein is reduced by 
40%. Conversely, miR-20a depletion resulted in 
increased LRF protein levels by 55%.  
MiR-20a induces p19ARF expression to a smaller 
extent than siLRF. However, miR-20a is a more 
efficient senescence inducer than siLRF, implying the
contribution of other factors to the senescence effct.  
It has been shown that E2F1 expression is also under 
the miR-20a control in MEFs. When miR-20a is highly 
expressed there is a decrease in E2F1 protein levels, to 
a greater degree than that after siLRF. Conversely, 
miR-20a depletion slightly enhances E2F1 expression. 
However, E2F1 silencing by siE2F1 in MEFs is not 
enough to induce senescence, whereas miR-20a  
overexpression in LRF-null MEF, with the concomitant 
E2F1 downregulation, significantly enhances 
senescence. In addition, miR-20a and not siLRF, can 
also increase p16INK4A protein levels, a key player in 
senescence pathway, both in wild type and LRF-null 
MEFs. 
The above data support the notion that miR-20a elicit d 
cellular senescence results mainly from LRF 
downregulation and consequent p19ARF upregulation, 
with the contribution of E2F1 down-regulation and 
p16INK4A induction. 
P-glycoprotein (Pgp) and transcriptional 
repression of Pokemon 
Note 
Pgp is a 170 kD protein, encoded by the human MDR1 
(ABCB1) gene and belongs to the ATP-binding 
cassette transporters family. Pgp and the other family 
members function as pumps to extrude anticancer drugs 
from cancer cells and are related to drug resistance 
phenotype. Pgp is often over-expressed in drug-
resistant cancer cells. It has been found that Pgp 
represses the transcription of Pokemon, through 
decreasing Pokemon promoter activity. Furthermore, 
this Pgp regulated suppression of Pokemon is p53 
dependent. 
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